🔎 Trials Near Me

Home › Major Depressive Disorder › Washington

Major Depressive Disorder clinical trials in Washington

20 studies for Major Depressive Disorder are looking for participants at sites in Washington.

Cities in Washington

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

  • Core Clinical Research, Everett
  • Seattle Neuropsychiatric Treatment Center, Seattle
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397

Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  • Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT05850689

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  • Core Clinical Research, Everett
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  • Vanda Investigational Site, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

  • Seaport Investigator Site, Everett
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 14, 2026 · NCT07065240

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

  • Draig Clinical Site, Bellevue
  • Draig Clinical Site, Seattle
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  • Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 28, 2026 · NCT07573176

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

  • Draig Clinical Site, Bellevue
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 26, 2026 · NCT07300969

Positive Processes and Transition to Health (PATH)

  • University of Washington, Seattle
Recruiting
Ages 18 to 65 · All sexes · Updated Aug 19, 2026 · NCT06093906

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07226232

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  • Seattle Neuropsychiatric Treatment Center, Seattle
  • VA Portland Healthcare System, Vancouver
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

  • Northwest Clinical Research Center, Bellevue
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Aug 6, 2026 · NCT07412756

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  • Core Clinical Research, Everett
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 3, 2026 · NCT06775379

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Everett
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT06966401

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

  • Northwest Clinical Research Center /ID# 277484, Bellevue
  • Core Clinical Research /ID# 277518, Everett
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  • Seattle Neuropsychiatric Treatment Center, Bellevue
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

  • Autobahn Site #143, Bellevue
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jan 20, 2026 · NCT06633016

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Everett
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2025 · NCT06786624

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

  • Clinical Research Site, Everett
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jan 23, 2025 · NCT06223880

InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI

  • University of Washington Medical Center, Seattle
Recruiting
Ages 18 to 64 · All sexes · Updated Sep 19, 2024 · NCT06005194

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.